Top View
- Identification of Synergistic Drug Combinations Using Breast Cancer
- Addressing Challenges in Access to Oncology Medicines
- NINLARO® (Ixazomib) Oral Capsule
- Ninlaro® (Ixazomib) (Oral) Document Number: IC-0261 Last Review Date: 10/30/2018 Date of Origin: 12/04/2015 Dates Reviewed: 12/04/2015, 10/2016, 10/2017, 10/2018
- Marketed and Late Stage Pipeline
- Downloaded from Pub- Differentially Expressed Genes in COVID-19 That Also Chem [14]
- Ixazomib in Combination with Carboplatin in Pretreated Women
- The Cost Burden of Blood Cancer Care in Medicare a Longitudinal Analysis of Medicare Advantage and Fee for Service Patients Diagnosed with Blood Cancer
- Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results Simon J
- A Phase 0 Analysis of Ixazomib in Patients with Glioblastoma
- Page 1 of 6 REQUEST for JOINT PROJECT TEAM MEMBER
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- State and Specialty Pharmacy Drug Reimbursement Rates
- Takeda Oncology: Multiple Myeloma Treatment Options
- Ixazomib with Lenalidomide and Dexamethasone for Relapsed Or Refractory Multiple Myeloma
- NG161 NHS England Interim Treatment Options During the COVID 19 Pandemic
- Jatin J. Shah, MD Associate Professor Department of Lymphoma/Myeloma Division of Cancer Medicine the University of Texas MD Anderson Cancer Center Houston, Texas
- Bortezomib, Carfilzomib and Ixazomib Do Not Mediate Relevant Transporter‑Based Drug‑Drug Interactions
- Oral Chemotherapy: Convenience, Complexity, & the Pharmacist's Roel
- Information for Vermont Prescribers of Prescription Drugs NINLARO
- The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
- Ixazomib (Ninlaro®)
- Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib Against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
- Ixazomib with Lenalidomide and Dexamethasone (Ird)
- In Vitro and in Vivo E Cacy of the Novel Oral Proteasome Inhibitor NNU546
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- AHFS Pharmacologic-Therapeutic Classification System
- Standard Oncology Criteria Policy Number: Pending
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- Non-Preferred Drug List (NPDL)
- Takeda Quarterly Financial Report
- Paragraph IV Patent Certifications (PPIV)
- A Changing Paradigm in Cancer Care
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
- Neupogen, Neulasta, Nivestym, Fulphila, Udenyca, Ziextenzo
- HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use NINLARO Safely and Effec
- Bristol-Myers Squibb
- Prior Authorization Criteria Update: Oncology
- Trials Listing for Arizona Oncology Associates P.C
- NINLARO (Ixazomib) Is an Antineoplastic Agent
- Investigating Mechanisms Determining Cancer Cell Sensitivity to Carfilzomib and Novel Strategies to Overcome Resistance
- Do Not Tube List
- 5.01.540 Miscellaneous Oncology Drugs
- All ETCTN Trials
- UK Chemotherapy Board
- ISSUES Unlock the Potential of the Cancer
- Bmt Ctn 1302 Mm V1.0
- Ixazomib: the First Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
- Ninlaro, INN-Ixazomib
- Hazardous Drug List
- 208462Orig1s000
- Report on the Deliberation Results March 10, 2017 Pharmaceutical
- November 2020
- Pharmacology 101
- Helping Specialty Practices Increase Patient Access to Clinical Research Opportunities NOW AVAILABLE
- Dexamethasone for Induction Therapy Followed by Ixazomib Maintenance Treatment in Patients with Relapsed/Refractory Multiple Myeloma